Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Promoting, improving and accelerating the drug development and approval processes.

A I Graul

    Drug News & Perspectives
    |March 3, 2007
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The year's new drugs and biologics 2020.

    Drugs of today (Barcelona, Spain : 1998)·2021
    Same author

    The year's new drugs and biologics 2019.

    Drugs of today (Barcelona, Spain : 1998)·2020
    Same author

    The year's new drugs and biologics 2018: Part II - News that shaped the industry in 2018.

    Drugs of today (Barcelona, Spain : 1998)·2019
    Same author

    The year's new drugs and biologics 2018: Part I.

    Drugs of today (Barcelona, Spain : 1998)·2019
    Same author

    The year's new drugs & biologics, 2017, part II - News that shaped the industry in 2017.

    Drugs of today (Barcelona, Spain : 1998)·2018
    Same author

    The year's new drugs and biologics 2017: Part I.

    Drugs of today (Barcelona, Spain : 1998)·2018
    Same journal

    New drug discovery and development in India.

    Drug news & perspectives·2013
    Same journal

    Are we living in the end of the blockbuster drug era?

    Drug news & perspectives·2010
    Same journal

    Molecule of the Month. TAK-875.

    Drug news & perspectives·2010
    Same journal

    Epigenetic alterations of tumor marker microRNAs: towards new cancer therapies.

    Drug news & perspectives·2010
    Same journal

    Electroporation: a promising method for the nonviral delivery of DNA vaccines in humans?

    Drug news & perspectives·2010
    Same journal

    Trioxaquines: hybrid molecules for the treatment of malaria.

    Drug news & perspectives·2010
    See all related articles

    Regulatory agencies expedite new medicine development through programs like Phase 0 (microdosing), orphan drug initiatives, and FDA

    Area of Science:

    • Drug development and regulatory science.
    • Clinical trial innovation.
    • Pharmaceutical policy and rare diseases.

    Background:

    • New medicines require efficient development pathways.
    • Regulatory agencies aim to accelerate drug approval.
    • Addressing rare diseases and serious conditions is a priority.

    Purpose of the Study:

    • To review key drug development programs from regulatory agencies.
    • To highlight advancements in medicine acceleration and rare disease treatment.
    • To provide an overview of 2006 developments in these areas.

    Main Methods:

    • Review of three major drug development facilitation programs.
    • Analysis of regulatory initiatives: Phase 0/microdosing, orphan drugs, and fast track.

    Related Experiment Videos

  • Examination of developments in 2006.

    • Main Results:

    • Phase 0 (microdosing) eases early clinical transition.
    • Orphan drug programs encourage rare disease medicine development.
    • Fast track programs expedite review for serious unmet needs.

    Conclusions:

    • Regulatory programs significantly impact new medicine availability.
    • These initiatives demonstrate a commitment to public health needs.
    • Continued innovation in regulatory pathways is crucial for drug development.